Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole in Pediatric Nonerosive GERD (2–11 Years)
2022-501349-64-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of dexlansoprazole in Non-erosive Gastroesophageal Reflux Disease (NERD) (2 arms), sponsored by Takeda. Primary endpoint: Percentage of days without hurting or burning in the stomach, chest or throat over 12 weeks of treatment. Started Feb 2023; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on 2022-501349-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501349-64-00.